ROCO
4194
Market cap37mUSD
Nov 12, Last price
8.45TWD
Name
Holy Stone Healthcare Co Ltd
Chart & Performance
P/E
—
P/S
9.87
EPS
—
Div Yield, %
—
Shrs. gr., 5y
10.99%
Rev. gr., 5y
-10.27%
Revenues
119m
-49.86%
Net income
-183m
L-36.59%
CFO
-143m
L-48.55%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Holy Stone Healthcare Co., Ltd. engages in the research, development and manufacture of hyaluronic acid drugs and medical devices. It offers injectable devices for osteoarthritis and soft tissue injuries. The company also provides hyaluronic acid and mesalamine capsules for inflammatory bowel diseases. Holy Stone Healthcare was founded on January 18, 2001 and is headquartered in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||